ZAP Surgical Systems, Inc., a San Carlos, Calif.-based medical technology company developing a next-generation radiosurgical robot for non-invasive tumor ablation, completed an equity financing round that raised an aggregate total of US$81m.
The round was led by Primavera Capital Group, with participation from GT Healthcare Capital Partners, Chow Tai Fook Enterprises, ShangBay Capital, and Hogy Medical, who joined existing investors Foxconn Technology Group and Varian Medical Systems.
The company, which has now raised more than US$160m in financing capital to date, intends to use the funds to accelerate the commercialization of its FDA cleared ZAP-X® surgical robot for the treatment of cancer and other brain disorders.
Led by founder and CEO John R. Adler, MD, Stanford Professor of Neurosurgery, ZAP Surgical Systems ZAP Surgical Systems designs and manufactures the ZAP-X® radiosurgery platform, an integrated robotic software and hardware solution currently FDA-cleared to provide image-guided stereotactic radiosurgery for tumors, lesions and conditions in the brain, head and neck. ZAP-X incorporates a self-shielded design that typically eliminates the need for traditional radiation vaults, and thus enables simple point-of-care delivery in locations including physician offices, ambulatory surgery centers, and satellite facilities.